ARTBIO
Heng Li is an experienced professional in the field of biochemistry and molecular biology, currently serving as the Director of Early Discovery at ARTBIO, focusing on radioligand therapy since May 2024. Previously, Heng held the position of Scientific Director at 76Bio, Inc., where responsibilities included designing and establishing the Designer E3 Ligase Therapeutics platform and overseeing various stages of target selection and assay development. Prior roles include Associate Director and Principal Scientist at Kronos Bio, Inc., and Research Scientist at C4 Therapeutics, Inc., where expertise in E3 ligases and targeted protein degradation was developed. Heng's academic foundation includes a PhD in Biochemistry, Biophysics, and Molecular Biology from the University of Science and Technology of China, complemented by postdoctoral fellowships at the University of Washington and Howard Hughes Medical Institute.
ARTBIO
ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.